Genmab A/S (GMAB)

Etorro trading 970x250
Genmab A/S (GMAB) Logo

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company’s products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson’s disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. Address: Kalvebod Brygge 43, Copenhagen, Denmark, 1560

Genmab A/S News and around…

Latest news about Genmab A/S (GMAB) common stock and company :

Capital Increase in Genmab as a Result of Employee Warrant Exercise
17 May, 2022 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; May 17, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 450 shares at DKK 623.50,2,500 shares at DKK 636.50,2,800 shares at DKK 939.50,6,837 shares at DKK 1,025.00,773 sha

Johnson & Johnson Stock: A Rare Bright Spot in the Market
14 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility. The post Johnson & Johnson Stock: A Rare Bright Spot in the Market appeared first on InvestorPlace.

Analyst Ratings for Genmab
12 May, 2022 FinancialContent

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings: Bullish Somewhat ...

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
12 May, 2022 FinancialContent

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association (EHA) Annual Congress, being held in Vienna, Austria, and virtually, June 9-12. The presentations will include data from various clinical trials, including multiple arms of the phase 1b/2 EPCORE™ NHL-2 trial, evaluating the safety and preliminary efficacy of epcoritamab in combination with standard-of-care therapies for the treatment of B-cell non-Hodgkin lymphoma (NHL), including first-line, high-risk diffuse large B-cell lymphoma (DLBCL), relapsed or refractory DLBCL, and relapsed or refractory follicular lymphoma (FL). Epcoritamab is being co-developed by Genmab and AbbVie (NYSE: ABBV).

Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript
12 May, 2022 FinancialContent

GMAB earnings call for the period ending March 31, 2022.

Genmab Announces Financial Results for the First Quarter of 2022
11 May, 2022 Yahoo! Finance

May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first three months of 2021 to USD 1,856 million, resulting in royalty revenue of DKK 1,501 millionGenmab updates its 2022 financial guidance “During the first quarter of 2022, there were continued advancements in our pipeline, including the first patient dosed with DuoBody®-CD3xB7H4 (GEN1047), the presentation of

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
11 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Veru Suggested By FDA To ...

Should You Buy Genmab (GMAB) Ahead of Earnings?
10 May, 2022 Yahoo! Finance

Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
02 May, 2022 FinancialContent

Upgrades For First Interstate BancSystem Inc (NASDAQ:FIBK), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform ...

3 Things About BioNTech That Smart Investors Know
29 Apr, 2022 FinancialContent

It's unlikely to be a one-hit wonder. And that should be great for patient investors.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
19 Apr, 2022 Yahoo! Finance

Company Announcement Net sales of DARZALEX® in the first quarter of 2022 totaled USD 1,856 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. COPENHAGEN, Denmark; April 19, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD

Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
14 Apr, 2022 Yahoo! Finance

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
14 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer-BioNTech's ...

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
14 Apr, 2022 FinancialContent

Genmab A/S(NASDAQ: GMAB) andAbbVie Inc(NYSE: ABBV)announced topline results from the first cohortof the ...

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
13 Apr, 2022 Yahoo! Finance

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with chimeric antigen receptor (CAR) T-cell thera

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
13 Apr, 2022 FinancialContent

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2, clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with chimeric antigen receptor (CAR) T-cell therapy. Based on the topline results, the companies will engage global regulatory authorities to determine next steps.

BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
11 Apr, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing ...

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
08 Apr, 2022 FinancialContent

Johnson & Johnson's(NYSE: JNJ) Janssen haswon an arbitration againstGenmab A/S(NASDAQ: GMAB) on two ...

The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More
08 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Harpoon Announces Departure ...

Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
07 Apr, 2022 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; April 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. The arbitral tribunal issued an award on April 7, 2022, deciding both issues in favor of Janssen. Genmab has the right to seek review of the award, which it must do within a limited period of time. Such review should conclude with the issuance of a fi

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
29 Mar, 2022 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; March 29, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Gen

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab
29 Mar, 2022 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; March 29, 2022 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2022, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 13,187 restricted stock units to the new member of the Board of Directors and employees of the Company and the Company’s subsidiaries and 13,912 warrants to the emp

Passing of Genmab A/S’ Annual General Meeting
29 Mar, 2022 Yahoo! Finance

Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2022, the Annual Report for 2021 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2021 Compensation Report was approvedOne new member of the Board of Directors was elected, and five members of the Board of Directors were re-elected PricewaterhouseCoopers was re-elected as auditor of the CompanyThe proposal from the Board of Directors o

Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
18 Mar, 2022 Yahoo! Finance

Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.

Best Biotech Stocks To Buy In 2022
15 Mar, 2022 FinancialContent

Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and pharmaceuticals, genomics, and food and chemical manufacturing.

Genmab Announces the Nomination of a New Member of the Company’s Board of Directors
14 Mar, 2022 Yahoo! Finance

Company Announcement Genmab’s Board of Directors proposes that Elizabeth O’Farrell is elected as a new member of the Board of Directors COPENHAGEN, Denmark; March 14, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the Company’s Board of Directors nominates Elizabeth O’Farrell for election as a new member of the Board of Directors at the Annual General Meeting, which will be held on March 29, 2022. The Board of Directors initiated a replacement process for a candidate to replace Jonathan P

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
09 Mar, 2022 Yahoo! Finance

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
08 Mar, 2022 FinancialContent

Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL). Epcoritamab is being co-developed by Genmab and AbbVie (NYSE: ABBV).

Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer
01 Mar, 2022 Yahoo! Finance

Media Release COPENHAGEN, Denmark; March 1, 2022Genmab A/S (Nasdaq: GMAB) announced today that Birgitte Stephensen has been appointed to Chief Legal Officer and Chris Cozic has been appointed to Chief People Officer within the Genmab Executive Management Team and promoted to Executive Vice Presidents effective March 1, 2022. Birgitte Stephensen joined Genmab in 2002 and previously served as Genmab’s Senior Vice President, Intellectual Property Rights and Legal. Chris Cozic joined Genmab in 2017

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
25 Feb, 2022 Yahoo! Finance

Company Announcement COPENHAGEN, Denmark; February 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 190,202 restricted stock units to five members of management and employees of the company as well as the company's subsidiaries and 175,595 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. T

Genmab A/S (GMAB) is a NASDAQ Common Stock listed in , ,

970x250